Patient Resources

FAQs

A once weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

Improves insulin sensitivity by enhancing first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.
Lowers fasting and postprandial glucose concentrations,
Delays gastric emptying and decreases food intake, thereby resulting in weight loss.
Levocarnitine: also know as Vitamin BT, it is an amino acid that contributes
A dipeptide of lysine and methionine, contributes to energy formation by facilitating the breakdown of excess fat, and
channeling fatty acids to the mitochondria for energy production.
Participates in the conversion of branched chain amino acids into energy.
Works synergistically with tirzepatide to improve glycemic control in adults with type 2 diabetes mellitus.
Prolonged low levels of carnitine can lead to heart, liver and muscle problems.
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Used off-label for chronic obesity leading towards metabolic diseases.

Primarily belongs to the class of antidiabetic agents, more specifically glucagon-like peptide 1

Stimulates glucose-dependent insulin release from pancreatic islets.
Slows gastric emptying.
Inhibits inappropriate post-meal glucagon release, and reduces food intake.
FDA approved for patients with type 2 diabetes and chronic obesity leading towards metabolic diseases.
Nicotinamide Adenine Dinucleotide (NAD):
Interacts with various enzymes to coordinate DNA repair, gene expression, stress response, and energy metabolism.
Improve glucose tolerance and lipid metabolism.
Encourage higher levels of energy expenditure and physical activity, while suppressing age-related weight gain.
Declining NAD+ levels are closely related to the development of various metabolic disorders, including fatty liver disease and diabetes.
When added to semaglutide as an adjuvant ingredient, may help jumpstart weight loss process as NAD+
levels decrease under disturbed nutrient conditions, such as obesity.